Use of PCSO-524®(Antinol®) in a Pomeranian Dog with Degenerative Mitral Valve Disease (DMVD) and Cardiac Tumor of the Left Atrium

A 10-year old Pomeranian dog with degenerative mitral valve disease (DMVD) and cardiac tumor of the left atrium was treated with pimobendan, ramipril, and furosemide in conjunction with PCSO-524® (Antinol®) as supplemental therapy.

After the treatment, the dog showed improved ability to conduct various activities, increased appetite and ingestion, weight gain and disappearance of paroxysmal ventricular premature contraction (VPC).

The C-reactive protein (CRP), which is an inflammatory marker in dogs, also decreased to normal level within 21 days of PCSO-524® (Antinol®) supplementation.

. . . VIEW

. . . VIEW

A Persian cat aged 21 years was diagnosed with Dynamic Hypertrophic Obstructive Cardiomyopathy (HOCM) and treated with PCSO-524® (Antinol®) for 45 days.

The cat regained quality of life and daily activities such as grooming and walking, increased appetite, ingestion and weight gain after the treatment. Serum Amyloid A (SAA), which is an inflammatory marker in cats, was reduced down to normal after 15 days of PCSO-524® (Antinol®) administration.

 

. . . VIEW

. . . VIEW

Updated Study Topics

New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted

 

Discover More Studies
Click to see the digital library